Free CME from PeerView


Hematology CME

PSU, Penn State University
The Future is Now in MDS: Integrating Innovative, Risk-Adapted Therapies Into Patient Management
December 08, 2022
Penn State College of Medicine
Real-World, Real Innovation in DLBCL: Perspectives on Integrating Novel Antibody Platforms Into Patient Care
December 08, 2022
Medical Learning Institute, Inc.
Demystifying Cold Agglutinin Disease: A Visual Exploration of Mechanism, Diagnosis, and the Role of Complement Inhibition in Addressing Unmet Needs
December 08, 2022
PSU, Penn State University
Fixing the Target on Aggressive Lymphoma: Guidance on the Next Phase of Integrating Targeted Agents Into MCL and DLBCL Management
December 08, 2022
PVI, PeerView Institute for Medical Education
Following the Diagnostic Pathway for Cold Agglutinin Disease
November 08, 2022
PVI, PeerView Institute for Medical Education
Don’t Miss the Rare When Diagnosing and Treating Autoimmune Hemolytic Anemia: Focus on CAD
November 08, 2022
PVI, PeerView Institute for Medical Education
The Eye-Deal Connection in Multiple Myeloma: Establishing Ophthalmology-Oncology Relationships to Overcome Ocular Toxicity
September 30, 2022
PVI, PeerView Institute for Medical Education
An "Off-the-Shelf" Approach for Myeloma Care: Visualizing the Present and Future of BCMA Antibodies
September 29, 2022
Medical Learning Institute, Inc.
The Power of Personalized Medicine in AML: Linking Individualized Treatment to Enhanced Patient Outcomes
September 28, 2022
Medical Learning Institute, Inc.
Challenges and Changes With Targeted Options in CLL: Guidance on Making Evidence-Informed Upfront and Sequential Treatment Choices
September 28, 2022
Medical Learning Institute, Inc.
The “Innovation Moment” Arrives for MDS: Guidance on Building Personalized Management Plans to Improve Patient Outcomes
September 26, 2022
PVI, PeerView Institute for Medical Education
Moving Beyond Conventional Care for DLBCL: Oncology Nurse Leadership for the Effective and Safe Use of Innovative Antibody and Cellular Therapies
September 13, 2022
PVI, PeerView Institute for Medical Education
Rebooting the BTK Inhibitor Sequence in MCL: Team-Centered Guidance on the Personalized Selection of Covalent and Noncovalent BTK Inhibitors in Relapsed/Refractory Disease
September 01, 2022
PVI, PeerView Institute for Medical Education
Reaching the Next Level of Myeloma Patient Care: Oncology Nurse Guidance on Antibody Therapy and Novel Mechanisms of Action
August 10, 2022
Medical Learning Institute, Inc.
Building Real-World Bridges Between Clinicians and Patients With Myeloma: Guidance on Innovative Antibody Options
July 26, 2022
PVI, PeerView Institute for Medical Education
Upgrading the Sequential Therapy Tool Kit for B-Cell Malignancies: New Evidence on the Individualized Use of BTK Inhibitors in Relapsed/Refractory CLL/SLL and MCL
July 14, 2022
Medical Learning Institute, Inc.
New Rules for BTK Inhibitors in CLL: Benchmarks for Evidence-Based Treatment Selection, Sequencing, and Safety Management
July 14, 2022
Credits: 1.5 / MOC / NCPD
PVI, PeerView Institute for Medical Education
Rising to the Occasion: Improving Outcomes in Leukemia, Lymphoma, and Multiple Myeloma With CAR T-Cell Therapy in Community Practice
June 04, 2022
The Medical College of Wisconsin
Reaping the Rewards of Innovative Care in CLL: From Targeted Strategies to Cellular Therapy
May 24, 2022

Pages